Comprehensive Characterization and Building of National Registry of Von Hippel-Lindau Disease in Brazil

Overview

Journal Mol Genet Genomic Med

Specialty Genetics

Date 2023 Jan 10

PMID 36625343

Authors

Tabatha Nakakogue Dallagnol

Eduardo Da Cas

Odery Ramos Junior

Jose Claudio Casali-da-Rocha

Affiliations

Soon will be listed here.

Abstract

Background: Von Hippel-Lindau (VHL) disease is an autosomal dominant disorder caused by pathogenic variants in VHL gene. The common manifestations include hemangioblastomas (HB) of the central nervous system (CNS) and retina (RH); pheochromocytoma (PHEO); clear cell renal cell carcinoma (ccRCC); pancreatic and renal cysts (PRC) and pancreatic neuroendocrine neoplasm (PNEN).

Methods: The first characterization of VHL in Brazil was published in 2003 and included 20 families with a history of VHL. The aim of this study was to expand the previous Brazilian cohort to include more families, as well as to collect prospectively both clinical and molecular characteristics of patients with VHL to build the VHL Brazilian Registry (VHLBR). Patients with VHL were selected through review of data from medical records of experts and from social networks of support for families with VHL in Brazil.

Results: A total of 142 subjects representing 62 unrelated Brazilian families with VHL were registered. The mean age of VHL onset was 28.78 years old and 128 individuals (90.1%) had at least one VHL-related lesion. CNS HB was the most common manifestation occurring in 91 (71%) patients, followed by multiple PRC (48.4%), RH (39.8%), ccRCC (28.9%), PHEO (12.5%) and PNEN (7.8%). Of the 97 subjects whose presence of VHL variants was confirmed, 51 (52.6%) had missense variants, 22 (22.7%) large deletions, 10 (10.3%) frameshift, 7 (7.2%) splice site, 4 (4.1%) nonsense and 3 (3.1%) in-frame deletions. Regarding surveillance, 115 (81%) participants had at least one physician responsible for their outpatient follow-up; however, 69 (60%) of them did not report a regular frequency of tests.

Conclusion: We built the largest prospective VHLBR with organized collections of clinical and genetic data from families with VHL, which will be helpful to guide policies for VHL care and oncogenetics in Brazil. Although there have been improvements in diagnosis and clinical screening methods, VHL care in Brazil is still deficient, especially regarding surveillance and regular medical appointments with experts.

Citing Articles

Comprehensive characterization and building of National Registry of von Hippel-Lindau disease in Brazil.

Dallagnol T, Cas E, Ramos Junior O, Casali-da-Rocha J Mol Genet Genomic Med. 2023; 11(4):e2136.

PMID: 36625343 PMC: 10094063. DOI: 10.1002/mgg3.2136.

References

Chittiboina P, Lonser R . Von Hippel-Lindau disease. Handb Clin Neurol. 2015; 132:139-56. PMC: 5121930. DOI: 10.1016/B978-0-444-62702-5.00010-X. View

Lonser R, Glenn G, Walther M, Chew E, Libutti S, Linehan W . von Hippel-Lindau disease. Lancet. 2003; 361(9374):2059-67. DOI: 10.1016/S0140-6736(03)13643-4. View

Salama Y, Albanyan S, Szybowska M, Bullivant G, Gallinger B, Giles R . Comprehensive characterization of a Canadian cohort of von Hippel-Lindau disease patients. Clin Genet. 2019; 96(5):461-467. DOI: 10.1111/cge.13613. View

Glasker S, Vergauwen E, Koch C, Kutikov A, Vortmeyer A . Von Hippel-Lindau Disease: Current Challenges and Future Prospects. Onco Targets Ther. 2020; 13:5669-5690. PMC: 7305855. DOI: 10.2147/OTT.S190753. View

Rocha J, Silva R, Mendonca B, Marui S, Simpson A, Camargo A . High frequency of novel germline mutations in the VHL gene in the heterogeneous population of Brazil. J Med Genet. 2003; 40(3):e31. PMC: 1735383. DOI: 10.1136/jmg.40.3.e31. View

Feletti A, Anglani M, Scarpa B, Schiavi F, Boaretto F, Zovato S . Von Hippel-Lindau disease: an evaluation of natural history and functional disability. Neuro Oncol. 2016; 18(7):1011-20. PMC: 4896541. DOI: 10.1093/neuonc/nov313. View

Vergauwen E, Vanbinst A, Brussaard C, Janssens P, De Clerck D, Van Lint M . Central nervous system gadolinium accumulation in patients undergoing periodical contrast MRI screening for hereditary tumor syndromes. Hered Cancer Clin Pract. 2018; 16:2. PMC: 5756358. DOI: 10.1186/s13053-017-0084-7. View

Sgambati M, Stolle C, Choyke P, Walther M, Zbar B, Linehan W . Mosaicism in von Hippel-Lindau disease: lessons from kindreds with germline mutations identified in offspring with mosaic parents. Am J Hum Genet. 2000; 66(1):84-91. PMC: 1288351. DOI: 10.1086/302726. View

Neumann H, Wiestler O . Clustering of features of von Hippel-Lindau syndrome: evidence for a complex genetic locus. Lancet. 1991; 337(8749):1052-4. DOI: 10.1016/0140-6736(91)91705-y. View

10.

Richards F, Payne S, Zbar B, Affara N, Ferguson-Smith M, Maher E . Molecular analysis of de novo germline mutations in the von Hippel-Lindau disease gene. Hum Mol Genet. 1995; 4(11):2139-43. DOI: 10.1093/hmg/4.11.2139. View

11.

Binderup M, Galanakis M, Budtz-Jorgensen E, Kosteljanetz M, Bisgaard M . Prevalence, birth incidence, and penetrance of von Hippel-Lindau disease (vHL) in Denmark. Eur J Hum Genet. 2016; 25(3):301-307. PMC: 5315510. DOI: 10.1038/ejhg.2016.173. View

12.

Crossey P, Richards F, Foster K, Green J, Prowse A, Latif F . Identification of intragenic mutations in the von Hippel-Lindau disease tumour suppressor gene and correlation with disease phenotype. Hum Mol Genet. 1994; 3(8):1303-8. DOI: 10.1093/hmg/3.8.1303. View

13.

Maxwell P, Wiesener M, Chang G, Clifford S, Vaux E, Cockman M . The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 1999; 399(6733):271-5. DOI: 10.1038/20459. View

14.

Mettu P, Agron E, Samtani S, Chew E, Wong W . Genotype-phenotype correlation in ocular von Hippel-Lindau (VHL) disease: the effect of missense mutation position on ocular VHL phenotype. Invest Ophthalmol Vis Sci. 2010; 51(9):4464-70. PMC: 2941163. DOI: 10.1167/iovs.10-5223. View

15.

Maher E, Webster A, Richards F, Green J, Crossey P, Payne S . Phenotypic expression in von Hippel-Lindau disease: correlations with germline VHL gene mutations. J Med Genet. 1996; 33(4):328-32. PMC: 1050584. DOI: 10.1136/jmg.33.4.328. View

16.

Maher E, Neumann H, Richard S . von Hippel-Lindau disease: a clinical and scientific review. Eur J Hum Genet. 2011; 19(6):617-23. PMC: 3110036. DOI: 10.1038/ejhg.2010.175. View

17.

Ong K, Woodward E, Killick P, Lim C, MacDonald F, Maher E . Genotype-phenotype correlations in von Hippel-Lindau disease. Hum Mutat. 2006; 28(2):143-9. DOI: 10.1002/humu.20385. View

18.

Zbar B, Kishida T, Chen F, Schmidt L, Maher E, Richards F . Germline mutations in the Von Hippel-Lindau disease (VHL) gene in families from North America, Europe, and Japan. Hum Mutat. 1996; 8(4):348-57. DOI: 10.1002/(SICI)1098-1004(1996)8:4<348::AID-HUMU8>3.0.CO;2-3. View

19.

Latif F, Tory K, Gnarra J, Yao M, Duh F, Orcutt M . Identification of the von Hippel-Lindau disease tumor suppressor gene. Science. 1993; 260(5112):1317-20. DOI: 10.1126/science.8493574. View

20.

Maher E, Iselius L, Yates J, Littler M, Benjamin C, Harris R . Von Hippel-Lindau disease: a genetic study. J Med Genet. 1991; 28(7):443-7. PMC: 1016952. DOI: 10.1136/jmg.28.7.443. View